Fly News Breaks for June 5, 2015
VRTX
Jun 5, 2015 | 09:12 EDT
After Vertex gained global rights to Parion’s (epithelial sodium channel inhibitors, P-1037 and P-1055, JMP Securities says the pipeline improves the competitive edge of Vertex's cystic fibrosis franchise. The firm says it believes that Parion;s approach may work across all Cf genotypes. the firm keeps a $152 price target and Outperform rating on Vertex.
News For VRTX From the Last 2 Days
There are no results for your query VRTX